Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2008

View Archived Issues

Nerviano reports on phase I trials with the pan Aurora kinase inhibitor PHA-7393558

New agents for blood coagulation disorders claimed in recent patents

PMI-150 enters pivotal study in acute pain

M.D. Anderson and Aureon to evaluate non-small cell lung cancer biomarkers

Amitiza filed for chronic idiopathic constipation in Switzerland

Improved glucose tolerance and insulin sensitivity by CNTO-530 in diabetic mice

UCB and Otsuka to codevelop and copromote Keppra and Cimzia in Japan

Astex and Janssen establish cancer research alliance

Radius selects preclinical SARM candidate for sarcopenia

Novel GPR119 agonist shows antidiabetic activity in vivo

First phase III study of AZ-004 for acute agitation completes enrollment

Peplin to acquire Neosil

AMT obtains license to use microRNA technology in hemophilia B therapy

Increase in bone mineral density seen with lasofoxifene treatment

Kamada reports advances in development of aerosolized AAT

Phase III trial of Lymphoseek begins

Entereg available for postoperative ileus

Oncolin collaborates with leading cancer center for glycolysis inhibitors

Noxxon and Lilly collaborate on Spiegelmers discovery and development

Epix initiates second trial in phase IIb Alzheimer's disease program

Positive preclinical profile of Pfizer's novel nicotinic alpha7 agonist PHA-709829

Allergan to acquire Aczone Gel

Antisoma completes acquisition of Xanthus Pharmaceuticals

Merrimack raises USD 60 million in private financing to advance pipeline

Daiichi patent claims use of cetraxate hydrochloride for influenza

Recent Japan Tobacco patent discloses novel a uric acid transporter 1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...